Daniel J. Smith

Daniel J. Smith

Auto-generated profile, based on publicly available information

Daniel J. Smith

Clinical Director of Cystic Fibrosis and Bronchiectasis Services, Thoracic and Cystic Fibrosis Physician, Adult Cystic Fibrosis Centre, The Prince Charles Hospital Brisbane Queensland Australia

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
GMGraeme Mattison
Graeme Mattison
OCOliver J Canfell
Oliver J Canfell
DFDoug Forrester
Doug Forrester
CDChelsea Dobbins
Chelsea Dobbins
DSDaniel Smith
Daniel Smith
CSClair Sullivan
Clair Sullivan
Background: Chronic diseases contribute to high rates of disability and mortality. Patient engagement in chronic disease self-management is an essential component of chronic disease models of health care. Wearables provide patient-centered health data in real time, which can help inform self-management decision-making. Despite the perceived benefits of wearables in improving chronic disease self-management, their influence on health care outcomes remains poorly understood. Objective: This review aimed to examine the influence of wearables on health care outcomes in individuals with chronic diseases through a systematic review of the literature. Methods: A narrative systematic review was conducted by searching 6 databases for randomized and observational studies published between January 1, 2016, and July 1, 2021, that included the use of a wearable intervention in a chronic disease group to assess its impact on a predefined outcome measure. These outcomes were defined as any influence on the patient or clinician experience, cost-effectiveness, or health care outcomes as a result of the wearable intervention. Data from the included studies were extracted based on 6 key themes, which formed the basis for a narrative qualitative synthesis. All outcomes were mapped against each component of the Quadruple Aim of health care. The guidelines of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement were followed in this study. Results: A total of 30 articles were included; studies reported 2446 participants (mean age: range 10.1-74.4 years), and the influence of 14 types of wearables on 18 chronic diseases was presented. The most studied chronic diseases were type 2 diabetes (4/30, 13%), Parkinson disease (3/30, 10%), and chronic lower back pain (3/30, 10%). The results were mixed when assessing the impact on a predefined primary outcome, with 50% (15/30) of studies finding a positive influence on the studied outcome and 50% (15/30) demonstrating a nil effect. There was a positive effect of 3D virtual reality systems on chronic pain in 7% (2/30) of studies that evaluated 2 distinct chronic pain syndromes. Mixed results were observed in influencing exercise capacity; weight; and biomarkers of disease, such as hemoglobin A1c, in diabetes. In total, 155 outcomes were studied. Most (139/155, 89.7%) addressed the health care outcomes component. This included pain (11/155, 7.5%), quality of life (7/155, 4.8%), and physical function (5/155, 3.4%). Approximately 7.7% (12/155) of outcome measures represented the patient experience component, with 1.3% (2/155) addressing the clinician experience and cost. Conclusions: Given their popularity and capability, wearables may play an integral role in chronic disease management. However, further research is required to generate a strong evidence base for safe and effective implementation. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42021244562; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=244562

1 July 2010 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
DSD.J. Smith
D.J. Smith
Stephanie YerkovichStephanie Yerkovich
Stephanie Yerkovich
MTM.A. Towers
M.A. Towers
MCM.L. Carroll
M.L. Carroll
RTR. Thomas
R. Thomas
JUJ.W. Upham
J.W. Upham
The soluble receptor for advanced glycation end-products (sRAGE) has anti-inflammatory properties, and deficiency of circulating sRAGE is associated with various human diseases. Whether sRAGE concentrations are reduced in chronic obstructive pulmonary disease (COPD) has not been determined. The aim of this study was to determine plasma levels of sRAGE in COPD patients and establish whether sRAGE varies in relation to forced expiratory volume in 1 s (FEV1) and other inflammatory markers.61 COPD patients and 42 healthy controls were recruited. Plasma sRAGE, C-reactive protein (CRP) and serum amyloid A (SAA) were measured in patients with stable COPD. A subgroup had measurements during acute exacerbations of COPD (AECOPD).sRAGE was significantly lower in stable COPD than in healthy controls (p<0.001), while CRP (p<0.001) and SAA (p = 0.015) were higher in stable COPD than in healthy controls. Multiple linear regression confirmed that COPD was negatively associated with sRAGE (p<0.001). Plasma sRAGE was positively correlated with FEV1(r2= 0.530, p<0.001), while CRP and SAA were inversely proportional to FEV1. Multiple linear regression analysis showed that only sRAGE was a strong predictor of FEV1. AECOPD were associated with even lower sRAGE levels that increased with convalescence.Circulating sRAGE is lower in COPD and shows a strong correlation to the degree of airflow limitation.

1 May 2014 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
DSDaniel J. Smith
Daniel J. Smith
Greg AndersonGreg Anderson
Greg Anderson
SBScott C. Bell
Scott C. Bell
DRDavid Reid
David Reid

17 July 2014 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
DSDaniel J. Smith
Daniel J. Smith
ABAlison C. Badrick
Alison C. Badrick
MZMartha Zakrzewski
Martha Zakrzewski
LKLutz Krause
Lutz Krause
SBScott C. Bell
Scott C. Bell
DRDavid Reid
David Reid
Chronic airway infection in adults with cystic fibrosis (CF) is polymicrobial and the impact of intravenous antibiotics on the bacterial community composition is poorly understood. We employed culture-independent molecular techniques to explore the early effects ofi.v.antibiotics on the CF airway microbiome.DNA was extracted from sputum samples collected from adult subjects with CF at three time-points (before starting treatment, and at day 3 and day 8–10 ofi.v.antibiotics) during treatment of an infective pulmonary exacerbation. Microbial community profiles were derived through analysis of bacterial-derived 16S ribosomal RNA by pyrosequencing and changes over time were compared.59 sputum samples were collected during 24 pulmonary exacerbations from 23 subjects. Between treatment onset and day 3 there was a significant reduction in the relative abundance ofPseudomonasand increased microbial diversity. By day 8–10, bacterial community composition was similar to pre-treatment. Changes in community composition did not predict improvements in lung function.The relative abundance ofPseudomonasfalls rapidly in subjects with CF receivingi.v.antibiotic treatment for a pulmonary exacerbation and is accompanied by an increase in overall microbial diversity. However, this effect is not maintained beyond the first week of treatment.

8 November 2012 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
DSDaniel J. Smith
Daniel J. Smith
Iain LamontIain Lamont
Iain Lamont
GAGreg J. Anderson
Greg J. Anderson
DRDavid Reid
David Reid
The aerobic Gram-negative bacteriumPseudomonas aeruginosais an opportunistic pathogen responsible for life-threatening acute and chronic infections in humans. As part of chronic infectionP. aeruginosaforms biofilms, which shield the encased bacteria from host immune clearance and provide an impermeable and protective barrier against currently available antimicrobial agents.P. aeruginosahas an absolute requirement for iron for infection success. By influencing cell–cell communication (quorum sensing) and virulence factor expression, iron is a powerful regulator ofP. aeruginosabehaviour. Consequently, the imposed perturbation of iron acquisition systems has been proposed as a novel therapeutic approach to the treatment ofP. aeruginosabiofilm infection.In this review, we explore the influence of iron availability onP. aeruginosainfection in the lungs of the people with the autosomal recessive condition cystic fibrosis as an archetypal model of chronicP. aeruginosabiofilm infection. Novel therapeutics aimed at disruptingP. aeruginosaare discussed, with an emphasis placed on identifying the barriers that need to be overcome in order to translate these promisingin vitroagents into effective therapies in human pulmonary infections.

8 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DSDaniel J Smith
Daniel J Smith
GHGeoffrey R Hill
Geoffrey R Hill
SBScott C Bell
Scott C Bell
DRDavid Reid
David Reid
Primary defects in host immune responses have been hypothesised to contribute towards an inability of subjects with cystic fibrosis (CF) to effectively clear pulmonary infections. Innate T-lymphocytes provide rapid pathogen-specific responses prior to the development of classical MHC class I and II restricted T-cell responses and are essential to the initial control of pulmonary infection. We aimed to examine the relationship between peripheral blood lymphocyte phenotype and clinical outcomes in adults with CF. We studied 41 subjects with CF and 22, age matched, non-smoking healthy control subjects. Lymphocytes were extracted from peripheral blood samples and phenotyped by flow-cytometry. Lymphocyte phenotype was correlated with sputum microbiology and clinical parameters. In comparison to healthy control subjects, mucosal associated invariant T (MAIT)-lymphocytes were significantly reduced in the peripheral blood of subjects with CF (1.1% versus 2.0% of T-lymphocytes, P = 0.002). MAIT cell concentration was lowest in CF subjects infected with P. aeruginosa and in subjects receiving treatment for a pulmonary exacerbation. Furthermore a reduced MAIT cell concentration correlated with severity of lung disease. Reduced numbers of MAIT cells in subjects with CF were associated with P. aeruginosa pulmonary infection, pulmonary exacerbations and more severe lung disease. These findings provide the impetus for future studies examining the utility of MAIT cells in immunotherapies and vaccine development. Longitudinal studies of MAIT cells as biomarkers of CF pulmonary infection are awaited.